Dupilumab, a monoclonal antibody that blocks interleukin 4 and interleukin 13, has been approved for eosinophilic esophagitis (EoE), a chronic disease characterized by symptoms of esophageal dysfunction and eosinophil‐predominant inflammation which frequently associated with IgE sensitization to food allergens. Here, IL4 is linked to eosinophilic esophagitis.